Stemline Therapeutics (NASDAQ:STML)

CAPS Rating: 3 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar clangmead (58.81) Submitted: 3/9/2016 6:06:38 AM : Outperform Start Price: $5.25 STML Score: -0.51

mpor1

Recs

2
Member Avatar zzlangerhans (99.78) Submitted: 12/15/2013 10:57:02 AM : Outperform Start Price: $20.32 STML Score: -88.16

No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more attractive for a narrowly focused biopharma headed into pivotal trials of a largely unproven therapy for a potentially lucrative indication. Lock-up expiration activity is likely resolved and hedge fund transactions have lately been favorable. If the momentum reverses once the pivotal trials kick off in early 2014, I might tag a small chunk of speculative capital onto Stemline for the ride.

Results 1 - 2 of 2

Featured Broker Partners